Filing identity and reporting period
Important mismatch: The supplied filing is Silverback Therapeutics, Inc.’s Form 10-K, not an ARS Pharmaceuticals, Inc. filing. It covers the fiscal year ended December 31, 2021; it is not a standalone fourth-quarter report. The filing was signed March 31, 2022.
Business context
Silverback was a clinical-stage biopharmaceutical company developing tissue-targeted therapeutics using its ImmunoTAC platform. At year-end, its programs included oncology candidates SBT6050 and SBT6290 and preclinical SBT8230 for chronic hepatitis B (cHBV). It had no approved products and generated no product revenue.
Financial performance and liquidity
| Metric | FY2021 | FY2020 |
|---|---|---|
| Revenue | None reported | None reported |
| Research and development expense | $61.5 million | $24.6 million |
| General and administrative expense | $28.1 million | $8.3 million |
| Total operating expenses | $89.6 million | $32.9 million |
| Net loss | $89.5 million | $32.9 million |
| Net loss per share, basic and diluted | $2.56 | $11.33 |
| Net cash used in operating activities | $66.8 million | $31.2 million |
Cash, cash equivalents, restricted cash and investments totaled $319.1 million at December 31, 2021, versus $386.9 million in cash and restricted cash at December 31, 2020 (no investments were reported at that date). Management estimated that year-end 2021 resources, reflecting the March 2022 restructuring plan, would fund operations and capital needs into the second half of 2026. The company cautioned that it would need substantial additional capital to take candidates through regulatory approval.
Total assets were $333.5 million and total liabilities were $19.7 million at year-end. The $3.5 million term loan was fully repaid in May 2021; remaining reported liabilities were primarily lease obligations and operating accruals. The filing reports no operating margins because there was no revenue. Operating lease obligations totaled $6.9 million undiscounted.
Changes, outlook, risks and unusual items
- Year-over-year net loss increased by $56.5 million, or 172%, as R&D and G&A spending expanded. R&D costs rose with clinical and preclinical work and higher staffing; G&A growth reflected personnel, professional fees and public-company costs.
- On March 28, 2022, after the reporting year, Silverback decided to discontinue SBT6050 and SBT6290 and focus resources on SBT8230 and early discovery. SBT6050 had limited monotherapy antitumor activity; combination treatment with pembrolizumab produced dose-limiting and later-cycle adverse events and did not produce RECIST responses in the reported combination cohort. SBT6290 was stopped before patient dosing.
- Management planned a Phase 1 regulatory submission for SBT8230 in Q4 2022 and a first-in-human single-ascending-dose study in healthy volunteers in the first half of 2023, followed by a multiple-ascending-dose study in virally suppressed cHBV patients. These were plans, not achieved milestones.
- The restructuring included a planned 27% workforce reduction, expected to be substantially completed by July 15, 2022, and approximately $2.0 million of cash termination-benefit costs in 2022.
- Principal risks include early-stage clinical and regulatory uncertainty, potential safety or immune-related adverse events, reliance on third-party manufacturers and CROs, COVID-19-related supply and trial disruption, competition, patent and licensing uncertainty, and future financing needs. A securities class action concerning statements about SBT6050 was pending; the company had not recorded a liability because the outcome and loss range could not be reasonably estimated.
- The financial statements received an unqualified audit opinion from Ernst & Young LLP. The auditor did not attest to internal control over financial reporting; management reported controls effective as of December 31, 2021.
Investor facts to verify
- Confirm the intended issuer: this filing identifies Silverback Therapeutics (ticker SBTX), not ARS Pharmaceuticals.
- Review the audited statements and notes for cash composition, investment valuation, lease commitments, and the absence of outstanding term debt.
- Check subsequent filings for actual SBT8230 regulatory and clinical milestones, spending, runway updates, and restructuring costs.
- Track the status and potential financial exposure of the securities class action and any developments affecting SBT8230 intellectual property or licensing.
- Assess whether projected runway assumptions remain valid and whether additional financing, dilution, or partnerships may be needed.